PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services, the company announced this week.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Under the agreement, the parties will first collaborate in a joint, multi-center, pilot trial of PatenSee's contactless monitoring system in Fresenius Medical Care's dialysis clinics in Israel.
The study is expected to commence during Q1 2024. PatenSee plans to add additional clinics in the United States, to collect the required data toward FDA clearance.
"Timely monitoring and analysis of the fistula status of hemodialysis patients are major clinical unmet needs and PatenSee's contactless, rapid monitoring has the potential to make a significant impact in dialysis patients," said Adi Shaked, venture innovation manager-Israel at Fresenius Medical Care, which is leading the collaboration from the Fresenius Medical Care Ventures team, along with Dr. Alon Antebi, country medical director at Fresenius Medical Care, Israel.
Chairman of PatenSee Shai Policker said, "PatenSee's goal is to enhance the quality of patient monitoring and reduce complications while alleviating the burden on clinical staff. We are happy to start this new phase of implementing PatenSee's contactless monitoring technology and even happier to perform this study in collaboration with Fresenius Medical Care with its wealth of experience and clinical expertise."
